KRYS - Company ID 0001711279
The table below shows Krystal Biotech, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $389.13M | $290.51M | $50.70M | $0.00 | $0.00 | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $58.05M | $53.58M | $46.43M | $42.46M | $27.88M | $17.94M |
| SG&A |
Krystal Biotech, Inc. reported annual revenue of $389.13M for fiscal year 2025. That is up 33.9% from $290.51M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $146.74M |
| $113.63M |
| $98.29M |
| $77.73M |
| $40.39M |
| $15.06M |
| Operating income | $161.29M | $65.75M | -$109.62M | -$145.20M | -$68.28M | -$33.00M |
| Income tax | -$15.36M | $6.20M | $1.97M | $0.00 | $0.00 | $0.00 |
| Net income | $204.83M | $89.16M | $10.93M | -$139.97M | -$69.57M | -$32.17M |
| EPS (diluted) | $6.84 | $3.00 | $0.39 | -$5.49 | -$3.13 | -$1.71 |